PET Molecular imaging of hypoxia in ischemic stroke: An update

Current Vascular Pharmacology

Volumn 13, Issue 2, 2015, Pages 209-217

  Baskin, Aylin ^a   Buchegger, Franz ^a,b   Seimbille, Yann ^a,b   Ratib, Osman ^a,b   Garibotto, Valentina ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Hypoxia; PET; Stroke

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; NITROIMIDAZOLE; RADIOPHARMACEUTICAL AGENT; OXYGEN;

ANGIOCARDIOGRAPHY; ARTICLE; BRAIN ISCHEMIA; CAROTID ARTERY DISEASE; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; FUNCTIONAL NEUROIMAGING; HUMAN; HYPOXIA; INFLAMMATION; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN EXTRACTION FRACTION; POSITRON EMISSION TOMOGRAPHY; RISK ASSESSMENT; ULTRASOUND; ANIMAL; BRAIN; BRAIN CIRCULATION; DISEASE MODEL; HYPOXIA, BRAIN; METABOLISM; PATHOPHYSIOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR; SCINTISCANNING; STROKE; VASCULARIZATION;

ANIMALS; BRAIN; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; HUMANS; HYPOXIA, BRAIN; OXYGEN; PATIENT SELECTION; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; RISK FACTORS; STROKE;

EID: 84929730853     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113116660167     Document Type: Article

References (81)

1. Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003; 2: 43-53
2. Heiss WD. The ischemic penumbra: correlates in imaging and implications for treatment of ischemic stroke. The Johann Jacob Wepfer award 2011. Cerebrovasc Dis 2011; 32: 307-20
3. Michiels C. Physiological and pathological responses to hypoxia. Am J Pathol 2004; 164: 1875-82
4. Heiss WD, Graf R, Wienhard K, et al.Dynamic penumbra demonstrated by sequential multitracer PET after middle cerebral artery occlusion in cats. J Cereb Blood Flow Metab 1994; 14: 892-902
5. Touzani O, Young AR, Derlon J-M, et al.Sequential studies of severely hypometabolic tissue volumes after permanent middle cerebral artery occlusion: A positron emission tomographic investigation in anesthetized baboons. Stroke 1995; 26: 2112-9
6. von Kummer R. After european cooperative acute stroke study 3: mission accomplished? Stroke 2009; 40: 2268-70
7. Vaupel P, Schlenger K, Knoop C, Höckel M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 1991; 51: 3316-22
8. Kavanagh MC, Sun A, Hu Q, Hill RP. Comparing techniques of measuring tumor hypoxia in different murine tumors: Eppendorf pO2 Histograph, [3H]misonidazole binding and paired survival assay. Radiat Res 1996; 145: 491-500
9. Kim JG, Song Y, Zhao D, Constantinescu A, Mason RP, Liu H, editors. Interplay of tumor vascular oxygenation and pO[sub 2] in tumors using NIRS and needle electrode. Optical Tomography and Spectroscopy of Tissue IV; 2001; San Jose, CA, USA: SPIE
10. Mason RP, Hunjan S, Constantinescu A, et al.Tumor oximetry: comparison of 19F MR EPI and electrodes. Adv Exp Med Biol 2003; 530: 19-27
11. Davda S, Bezabeh T. Advances in methods for assessing tumor hypoxia in vivo: implications for treatment planning. Cancer Metastasis Rev 2006; 25: 469-80
12. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med 2008; 49(Suppl 2): 129S-48S
13. Zaro-Weber O, Moeller-Hartmann W, Heiss WD, Sobesky J. The performance of MRI-based cerebral blood flow measurements in acute and subacute stroke compared with 15O-water positron emission tomography: identification of penumbral flow. Stroke 2009; 40: 2413-21
14. Sobesky J. Refining the mismatch concept in acute stroke: lessons learned from PET and MRI. J Cereb Blood Flow Metab 2012; 32: 1416-25
15. Derdeyn CP, Videen TO, Yundt KD, et al.Variability of cerebral blood volume and oxygen extraction: stages of cerebral haemodynamic impairment revisited. Brain 2002; 125: 595-607
16. Derdeyn CP, Grubb RL, Powers WJ. Cerebral hemodynamic impairment. Neurology 1999; 53: 251-9
17. Heiss WD, Graf R, Fujita T, et al.Early detection of irreversibly damaged ischemic tissue by flumazenil positron emission tomography in cats. Stroke 1997; 28: 2045-51
18. Heiss WD, Kracht L, Grond M, et al.Early [(11)C]Flumazenil/H(2)O positron emission tomography predicts irreversible ischemic cortical damage in stroke patients receiving acute thrombolytic therapy. Stroke 2000; 31: 366-9
19. Heiss WD, Grond M, Thiel A, et al.Permanent cortical damage detected by flumazenil positron emission tomography in acute stroke. Stroke 1998; 29: 454-61
20. Chapman JD, Franko AJ, Sharplin J. A marker for hypoxic cells in tumours with potential clinical applicability. Br J Cancer 1981; 43: 546-50
21. Prekeges JL, Rasey JS, Grunbaum Z, Krohn KH. Reduction of fluoromisonidazole, a new imaging agent for hypoxia. Biochem Pharmacol 1991; 42: 2387-95
22. Rasey JS, Martin GV, Krohn KA. Quantifying hypoxia with radiolabeled fluoromisonidazole: Pre-clinical and clinical studies. In: Machulla H-J eCP, editor., editor. The Imaging of Hypoxia Developments in Nuclear Medicine: Kluwer Academic Publishers; Dordrecht, The Netherlands; 1999. p. 85-117
23. Zanzonico P, O'Donoghue J, Chapman JD, et al.Iodine-124- labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging 2004; 31: 117-28
24. Ballinger J. Imaging hypoxia in tumors. Semin Nucl Med 2001; 31: 321-9
25. Biskupiak JE, Grierson JR, Rasey JS, Martin GV, Krohn KA. Synthesis of an (iodovinyl)misonidazole derivative for hypoxia imaging. J Med Chem 1991; 34: 2165-8
26. Nunn ALK, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995; 22: 265-80
27. Koch CJ, Evans SM. Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles. Adv Exp Med Biol 2003; 510: 285-92
28. Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF. Hypoxia in human gliomas: demonstration by PET with fluorine- 18-fluoromisonidazole. J Nucl Med 1992; 33: 2133-7
29. Lapi SE, Voller TF, Welch MJ. Positron Emission Tomography Imaging of Hypoxia. PET Clin 2009; 4: 39-47
30. Flockhart IR, Large P, D. T, Malcolm SL, Marten TR. Pharmacokinetic and metabolic studies of the hypoxic cell radiosensitizer misonidazole. Xenobiotica 1978; 8: 97-105
31. Tochon-Danguy HJSJ, Chan F, Chan JG, et al.Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F]fluoromisonidazole (FMISO). Nucl Med Biol 2002; 29: 191-7
32. Lee ST, Scott AM. Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole. Semin Nucl Med 2007; 37: 451-61
33. Grunbaum Z, Freauff SJ, Krohn KA, Wilbur DS, Magee S, Rasey JS. Synthesis and characterization of congeners of misonidazole for imaging hypoxia. J Nucl Med 1987; 28: 68-75
34. Koh WJ, Rasey JS, Evans ML, et al.Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992; 22: 199-212
35. Graham MM, Peterson LM, Link JM, et al.Fluorine-18- fluoromisonidazole radiation dosimetry in imaging studies. J Nucl Med 1997; 38: 1631-6
36. Takasawa M, Moustafa RR, Baron JC. Applications of nitroimidazole in vivo hypoxia imaging in ischemic stroke. Stroke 2008; 39: 1629-37
37. Machulla H-J. Imaging of Hypoxia. In: Cox PH e, editor. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1999
38. Sorger D, Patt M, Kumar P, et al. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 2003; 30: 317-26
39. Piert M, Machulla HJ, Picchio M, et al.Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 2005; 46: 106-13
40. Parliament MB, Chapman JD, Urtasun RC, et al.Non-invasive assessment of human tumour hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study. Br J Cancer 1992; 65: 90-5
41. Stypinski D, McQuarrie SA, Wiebe LI, Tam YK, Mercer JR, McEwan AJ. Dosimetry estimations for 123I-IAZA in healthy volunteers. J Nucl Med 2001; 42: 1418-23
42. Lythgoe MF, Williams SR, Busza AL, et al.The relationship between magnetic resonance diffusion imaging and autoradiographic markers of cerebral blood flow and hypoxia in an animal stroke model. Magn Reson Med 1999; 41: 706-14
43. Kaneta T, Takai Y, Iwata R, et al.Initial evaluation of dynamic human imaging using 18F-FRP170 as a new PET tracer for imaging hypoxia. Ann Nucl Med 2007; 21: 101-7
44. Kaneta T, Takai Y, Kagaya Y, et al.Imaging of ischemic but viable myocardium using a new 18F-labeled 2-nitroimidazole analog, 18F-FRP170. J Nucl Med 2002; 43: 109-16
45. Evans SM, Fraker D, Hahn SM, et al.EF5 binding and clinical outcome in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 2006; 64: 922-7
46. Evans SM, Judy KD, Dunphy I, et al.Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res 2004; 64: 1886-92
47. Koch CJ, Hahn SM, Rockwell K, Jr., Covey JM, McKenna WG, Evans SM. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1- yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2- nitroimidazoles. Cancer Chemother Pharmacol 2001; 48: 177-87
48. Blower PJ, Lewis JS, Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol 1996; 23: 957-80
49. Anderson CJ, Green MA, Fujibayashi Y. Chemistry of Copper Radionuclides and Radiopharmaceutical Products. In: Redvanly MWaC, editor. In Handbook of Radiopharmaceuticals: Radiochemistry and Applications: John Wiley & Sons, Ltd.; 2003. p. 401-22
50. Anderson CJ, Welch MJ. Radiometal-labeled agents (nontechnetium) for diagnostic imaging. Chem Rev 1999; 99: 2219-34
51. Smith S. Molecular imaging with copper-64. J Inorg Biochem 2004; 98: 1874-901
52. Vere AL, Lewis JS. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans 2007; 21: 4893-902
53. Laforest R, Dehdashti F, Lewis JS, Schwarz SW. Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET. Eur J Nucl Med Mol Imaging 2005; 32: 764-70
54. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997; 38: 1155-60
55. Fujibayashi Y, Cutler CS, Anderson CJ, et al.Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats. Nucl Med Biol 1999; 26: 117-21
56. Takahashi N, Fujibayashi Y, Yonekura Y, et al.Copper-62 ATSM as a hypoxic tissue tracer in myocardial ischemia. Ann Nucl Med 2001; 15: 293-6
57. Obata A YE, Waki A, Lewis JS, et al.Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent cudiacetyl- bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med 2001; 15: 499-504
58. Ikawa M, Okazawa H, Arakawa K, et al.PET imaging of redox and energy states in stroke-like episodes of MELAS. Mitochondrion 2009; 9: 144-8
59. Lewis JS, Herrero P, Sharp TL, et al.Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N(4)- methylthiosemicarbazone). J Nucl Med 2002; 43: 1557-69
60. Rasey JS, Hoffman JM, Spence AM, Krohn KA. Hypoxia mediated binding of misonidazole in non-malignant tissue. Int J Radiat Oncol Biol Phys 1986; 12: 1255-8
61. Hoffman JM, Rasey JS, Spence AM, Shaw DW, Krohn KA. Binding of the hypoxia tracer [3H]misonidazole in cerebral ischemia. Stroke 1987; 18: 168-76
62. Saita K, Chen M, Spratt NJ, et al.Imaging the ischemic penumbra with 18F-fluoromisonidazole in a rat model of ischemic stroke. Stroke 2004; 35: 975-80
63. Takasawa M, Beech JS, Fryer TD, et al.Imaging of brain hypoxia in permanent and temporary middle cerebral artery occlusion in the rat using 18F-fluoromisonidazole and positron emission tomography: a pilot study. J Cereb Blood Flow Metab 2007; 27: 679-89
64. Takasawa M, Beech JS, Fryer TD, et al.Single-subject statistical mapping of acute brain hypoxia in the rat following middle cerebral artery occlusion: a microPET study. Exp Neurol 2011; 229: 251-8
65. Read SJ, Hirano T, Abbott DF, et al.Identifying hypoxic tissue after acute ischemic stroke using PET and 18F-fluoromisonidazole. Neurology 1998; 51: 1617-21
66. Markus R, Reutens DC, Kazui S, et al.Hypoxic tissue in ischaemic stroke: persistence and clinical consequences of spontaneous survival. Brain 2004; 127: 1427-36
67. Read SJ, Hirano T, Abbott DF, et al.The fate of hypoxic tissue on 18F-fluoromisonidazole positron emission tomography after ischemic stroke. Ann Neurol 2000; 48: 228-35
68. Markus R, Reutens DC, Kazui S, et al.Topography and temporal evolution of hypoxic viable tissue identified by 18Ffluoromisonidazole positron emission tomography in humans after ischemic stroke. Stroke 2003; 34: 2646-52
69. Markus R, Donnan GA, Kazui S, et al.Statistical parametric mapping of hypoxic tissue identified by [(18)F]fluoromisonidazole and positron emission tomography following acute ischemic stroke. Neuroimage 2002; 16: 425-33
70. Falcao AL, Reutens DC, Markus R, et al.The resistance to ischemia of white and gray matter after stroke. Ann Neurol 2004; 56: 695-701
71. Hirano T, Read SJ, Abbott DF, et al.No evidence of hypoxic tissue on 18F-fluoromisonidazole PET after intracerebral hemorrhage. Neurology 1999; 53: 2179-82
72. Sarrafzadeh AS, Nagel A, Czabanka M, Denecke T, Vajkoczy P, Plotkin M. Imaging of hypoxic-ischemic penumbra with (18)Ffluoromisonidazole PET/CT and measurement of related cerebral metabolism in aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab 2010;30:36-45
73. Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999; 40: 177-83
74. Isozaki M, Kiyono Y, Arai Y, et al.Feasibility of 62Cu-ATSM PET for evaluation of brain ischaemia and misery perfusion in patients with cerebrovascular disease. Eur J Nucl Med Mol Imaging 2011; 38: 1075-82
75. Grubb RL, Jr., Derdeyn CP, Fritsch SM, et al.Importance of hemodynamic factors in the prognosis of symptomatic carotid occlusion. JAMA 1998; 280: 1055-60
76. Yamauchi H, Fukuyama H, Nagahama Y, et al.Significance of increased oxygen extraction fraction in five-year prognosis of major cerebral arterial occlusive diseases. J Nucl Med 1999; 40: 1992-8
77. Okazawa H, Kudo T. Clinical impact of hemodynamic parameter measurement for cerebrovascular disease using positron emission tomography and (15)O-labeled tracers. Ann Nucl Med 2009; 23: 217-27
78. Lees KR, Bluhmki E, von Kummer R, et al.Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 15: 1695-703
79. Grotta JC, Alexandrov AV. tPA-associated reperfusion after acute stroke demonstrated by SPECT. Stroke 1998; 29: 429-32
80. Powers W. Cerebral hemodynamics in ischemic cerebrovascular disease. Ann Neurol 1991; 29: 231-40
81. Bowen SR, van der Kogel AJ, Nordsmark M, Bentzen SM, Jeraj R. Characterization of positron emission tomography hypoxia tracer uptake and tissue oxygenation via electrochemical modeling. Nucl Med Biol 2011; 38: 771-80.